Structures by: Perumalla S.
Total: 10
Etoricoxib-adipic acid cocrystal
C18H15ClN2O2S,0.5(C6H10O4)
CrystEngComm (2016) 18, 16 2825
a=16.6417(18)Å b=5.4913(6)Å c=23.838(3)Å
α=90° β=98.603(2)° γ=90°
Etoricoxib-caprolactam dihydrate
2(C18H15ClN2O2S),C6H11NO,2(H2O)
CrystEngComm (2016) 18, 16 2825
a=12.552(3)Å b=12.574(3)Å c=14.989(3)Å
α=96.690(3)° β=114.553(2)° γ=90.099(3)°
Etoricoxib-gluraric acid cocrystal
C23H23ClN2O6S
CrystEngComm (2016) 18, 16 2825
a=11.8317(15)Å b=12.7266(16)Å c=15.772(2)Å
α=90° β=90.203(2)° γ=90°
Etoricoxib-suberic acid cocrystal
C18H15ClN2O2S,C8H14O4
CrystEngComm (2016) 18, 16 2825
a=9.0238(3)Å b=10.1284(5)Å c=14.8544(9)Å
α=82.766(5)° β=77.640(4)° γ=85.386(4)°
Etoricoxib-suberic acid cocrystal hydrate
2(C18H15ClN2O2S),0.5(C8H14O4),2(H2O),O
CrystEngComm (2016) 18, 16 2825
a=12.2796(15)Å b=12.4817(10)Å c=14.8713(18)Å
α=95.187(8)° β=113.754(12)° γ=91.242(8)°
C11H10N4O3
C11H10N4O3
Crystal Growth & Design (2015) 15, 2 858
a=7.7932(5)Å b=8.0164(5)Å c=10.2555(7)Å
α=76.952(5)° β=77.240(5)° γ=61.961(6)°
C11H10N4O3
C11H10N4O3
Crystal Growth & Design (2015) 15, 2 858
a=9.2881(4)Å b=9.9444(4)Å c=12.4340(5)Å
α=95.507(4)° β=106.560(4)° γ=90.488(4)°
C9H11N5O4
C9H11N5O4
Crystal Growth & Design (2015) 15, 2 858
a=5.2384(9)Å b=28.141(5)Å c=7.8234(13)Å
α=90.00° β=91.938(14)° γ=90.00°
C14H22N6O6
C14H22N6O6
Crystal Growth & Design (2015) 15, 2 858
a=8.5450(9)Å b=10.4099(9)Å c=11.0248(11)Å
α=64.251(9)° β=83.081(8)° γ=86.219(7)°
C12H12N2O8
C12H12N2O8
Crystal Growth & Design (2015) 15, 2 858
a=6.2822(2)Å b=13.4037(4)Å c=15.5274(6)Å
α=90.00° β=93.563(3)° γ=90.00°